OXALIPLATINE ACCORD 5 mg/ml
Sponsors
Institut Gustave Roussy, Gercor, Institut De Cancerologie De L Ouest, Association Gercor, Centre Hospitalier Universitaire Rouen
Conditions
Non-seminomatous germ-cell tumors (including testisPatients with metastatic pancreatic ductal adenocarcinoma.gastric and gastro-oesophageal junction adenocarcinomasmetastatic gastric adenocarcinomaresected pancreatic adenocarcinomaretroperitoneal and mediastinal primaries) with a disseminated disease (clinical stages II or III according to AJCC 8th edition) and classified as poor prognosis according to IGCCCG criteria.
Phase 2
A prospective program aiming at improving outcome for young adults with poor-prognosis non seminomatous germ-cell tumors (VAPOR (GETUG T06))
RecruitingCTIS2023-505040-19-00
Start: 2023-04-11Target: 150Updated: 2025-03-14
Gut microbiome intervention with EXL01 in combination with nivolumab and FOLFOX as first-line treatment for patients with PD-L1 CPS ≥5 metastatic gastric cancer: A randomized GERCOR phase II study (BIG)
RecruitingCTIS2023-506753-38-00
Start: 2024-04-16Target: 120Updated: 2025-10-02
Open-label non-randomized multicentric phase 2 study evaluating the combination of bemarituzumab + FLOT chemotherapy in perioperative setting for resectable stage cT2-T4a or N+ gastric and GEJ adenocarcinoma overexpressing FGFR2b (BEMAFLOT)
CompletedCTIS2024-514078-29-00
End: 2025-11-07Target: 49Updated: 2025-10-02
Pancreatic cancer first-line NALIRIFOX optimization with 5-FU maintenance and role of antibiotics and microbiota exploration in second-line treatment – A non-comparative, randomized phase II PANORAMIX GERCOR G-116 PRODIGE 105 study
Not yet recruitingCTIS2024-517766-41-00
Target: 142Updated: 2025-05-27
Risk-adapted adjuvant chemotherapy guided by the tumour stage for operated pancreatic adenocarcinoma following neoadjuvant chemotherapy with FOLFIRINOX
FRENCH26 – PRODIGE93 - PANACHE02 Trial
RecruitingCTIS2024-519048-33-00
Start: 2025-11-25Target: 390Updated: 2025-05-28